PVCTOTCPharmaceutical PreparationsUS GAAP · USD

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc. is a U.S.-based pharmaceutical preparations company focused on developing and commercializing drug candidates and related biopharmaceutical products. The company operates as a small-cap biotech issuer with activities centered in the United States and financing through equity-linked and convertible instruments.

Kysy yhtiöstä
Liikevaihto0,3milj. USD
−45,5 %v/v
Liikevoitto (EBIT)−5,3milj. USD
−16,8 %v/v
EBIT-marginaali−1 575,3%
−840,9 %-yks.v/v
Nettotulos−5,4milj. USD
−14,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−6−4−202milj. USD2020: EBIT −5,0 milj. USD20202021: EBIT −4,7 milj. USD20212022: 0,99 milj. USD2022: EBIT −3,4 milj. USD20222023: 0,56 milj. USD2023: EBIT −2,9 milj. USD20232024: 0,62 milj. USD2024: EBIT −4,5 milj. USD20242025: 0,34 milj. USD2025: EBIT −5,3 milj. USD20250,34−5,3
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Provectus Biopharmaceuticals, Inc.

Liiketoiminta

Osuus liikevaihdosta
Biopharmaceutical development70 %

Development of drug candidates and related pharmaceutical preparations.

Pharmaceutical preparations20 %

Formulation and preparation of pharmaceutical products and candidates.

Capital raising and financing instruments10 %

Convertible notes and preferred stock used to fund operations.

Asiakkaat

Provectus Biopharmaceuticals serves pharmaceutical and healthcare market participants that may license, develop, or commercialize its product candidates, along with investors that provide financing through convertible securities. In practice, the company’s value proposition is tied to advancing biopharmaceutical assets toward clinical, regulatory, or commercial milestones that can support partnering or future commercialization.

Pharmaceutical partners

Companies that may license, co-develop, or commercialize drug candidates.

Convertible note investors

Financing providers that supply unsecured convertible debt to fund operations.

Preferred stock holders

Investors receiving convertible preferred stock through debt conversion.

Potential commercial collaborators

Future partners that could support development or market access.

Strategia

Provectus appears focused on advancing its biopharmaceutical programs while maintaining access to external capital through convertible notes and preferred stock. The company’s strategic position depends on preserving development optionality, supporting operations, and converting scientific or product progress into financing or partnering value.

Advance product developmentKeskipitkä aikaväli

Clinical or development progress is the main driver of future value in a biopharmaceutical model.

Maintain financing accessLyhyt aikaväli

Convertible notes and preferred stock provide operating runway for a development-stage company.

Support optionality for partneringKeskipitkä aikaväli

Licensing or collaboration can reduce funding needs and accelerate commercialization.

Maantiede

The company is based in the United States and its disclosed activity is centered there. No country-level revenue disclosure was provided in the excerpts, so the geographic profile should be viewed as U.S.-anchored with potential exposure to international supply chains and trade policy through materials and equipment sourcing.

Riskit

The company faces development-stage biotech risks, including uncertainty around product progress, funding dependence, and dilution from convertible securities. Its reported risk factors also highlight exposure to U.S. trade policy changes that could raise the cost or disrupt the availability of materials, supplies, and equipment used in operations or by partners.

Järjestetty vakavuuden mukaan
Dependence on external financingKorkea

The company has relied on unsecured convertible notes and preferred stock conversions to fund operations.

Kohdistuu: Operating runway and dilution risk

Development and regulatory failureKorkea

Biopharmaceutical value depends on successful advancement of product candidates through development and approval pathways.

Kohdistuu: Pipeline and commercialization prospects

Shareholder dilution from convertible securitiesKorkea

Debt conversions into preferred stock increase share count and can reduce per-share value.

Kohdistuu: Capital structure

U.S. trade policy and tariff changesKeskitaso

Management disclosed that policy uncertainty could affect materials, supplies, and equipment costs or availability.

Kohdistuu: Operations and partner supply chains

Kysy Clarifolta: Provectus Biopharmaceuticals, Inc.

Kirjanpito

Harkinnanvaraiset erät
Convertible notes and embedded conversion features

These instruments can require complex liability/equity classification and fair value assessment.

Vaikutus: Affects debt balances, interest expense, and dilution

Preferred stock conversion accounting

Debt converted into Series D-1 Preferred Stock changes liabilities into equity and alters share counts.

Vaikutus: Affects balance sheet and equity presentation

Accrued interest on financing instruments

Interest accrued on notes is part of the conversion amount and impacts reported financing costs.

Vaikutus: Affects expenses and liabilities

Fair value estimates for financing instruments

Valuation judgments can materially affect reported amounts for convertible securities.

Vaikutus: Affects reported liabilities and equity

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Propanc Biopharma, Inc.

PPCB · Pharmaceutical Preparations

Liminatus Pharma, Inc.

LIMNW · Biological Products, (No Diagnostic Substances)

Pelthos Therapeutics Inc.

PTHS · Biological Products, (No Diagnostic Substances)

CTT Pharmaceutical Holdings, Inc.

CTTH · Pharmaceutical Preparations

Onconetix, Inc.

ONCO · Pharmaceutical Preparations

Oramed Pharmaceuticals Inc

ORMP · Pharmaceutical Preparations

Päivitetty: 24.9.2026